Health Condition 1: null- Scheduled for awake nasal fibreoptic intubation in view of assessed difficult airway
Conditions
Interventions
Intervention1: dexmedetomidine: 1 mcg/kg as bolus administered IV over 10 minutes prior to fibrescopy
Control Intervention1: midazolam and fentanyl: 1 mcg/kg fentanyl and 1 mg midazolam were administe
Sponsors
Kasturba Hospital KMC Manipal
Eligibility
Inclusion criteria
Inclusion criteria: All patients between 18-85 years undergoing awake nasal fibreoptic intubation
Exclusion criteria
Exclusion criteria: • ASA physical status IV • Raised intracranial pressure • Uncontrolled seizure disorder and/or known psychiatric illness • Current (in the past 14 days) treatment with an α2 agonist or antagonist • Patients in whom dexmedetomidine or benzodiazepine administration is contra-indicated • Patients with acute unstable angina, laboratory confirmed acute myocardial infarction within the past 6 weeks, heart rate • Patients with elevated SGPT (ALT) and/or SGOT (AST) values of > 2 times the upper limit of normal.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety and effectiveness of dexmedetomidine for sedation during awake nasal fiberoptic intubationTimepoint: Endoscopy time, intubation time and intubation score were done during and immediately following awake fibreoptic intubation | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse eventsTimepoint: during intubation and 24 h after surgery | — |
Countries
India
Contacts
Public ContactTajammul Sayeed
KMC, Manipal
Outcome results
None listed